Regulation of Cellular Plasticity in Mood Disorders: The Role of the AMPA Receptor

  • Per Svenningsson
  • Bruce S. McEwen


The pathophysiology of mood disorders has been an area of research for many years, but the precise neurobiological mechanisms that underpin these common conditions remain unclear. For much of the second half of the 20th century, the principal focus was on the role of monoamine neurotransmitters (in particular noradrenaline and serotonin, as well as dopamine) and their receptors, which are prominent in the limbic regions and prefrontal cortical areas that are known to be involved in many of the manifestations - both affective and physiological - of mood disorders. This focus has yielded an improved understanding of the neural mechanisms involved in mood disorders; moreover, it has led to the development of several major classes of antidepressant agents (notably the monoamine oxidase inhibitors, the tricylics, and the selective serotonin reuptake inhibitors [SSRIs]), all of which block either the oxidation of monoamines or their reuptake by neurons [1].


These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McEwen BS, Olié JP: Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry 2005; 10:525–37.PubMedCrossRefGoogle Scholar
  2. 2.
    Kasper S, McEwen BS: Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008; 22:15–26.PubMedCrossRefGoogle Scholar
  3. 3.
    Hindmarsh I: Expanding the horizons of depression: beyond the monoamine hypothesis. Hum Psychopharmacol 2001; 16:203–218.CrossRefGoogle Scholar
  4. 4.
    Svenningsson P, Bateup H, Hongshi Q, et al: Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci 2007; 26:3509–3517.PubMedCrossRefGoogle Scholar
  5. 5.
    Rajkowska G: Cell pathology in mood disorders. Semin Clin Neuropsychiatry 2002; 7:281–292.PubMedCrossRefGoogle Scholar
  6. 6.
    Zarate CA, Quiroz J, Payne J, Manji HK: Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002; 36:35–83.PubMedGoogle Scholar
  7. 7.
    Shah PJ, Ebemeir KP, Balabus MF, Goodwin GM: Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 1998; 172:527–532.PubMedCrossRefGoogle Scholar
  8. 8.
    Sapolsky RM: Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sic U S A 2001; 98; 12320–12322.CrossRefGoogle Scholar
  9. 9.
    Sheline Y, Sanghavi M, Muntun MA, Gado MH: Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 19:5034–5043.PubMedGoogle Scholar
  10. 10.
    Manji HK, Duman RS: Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001; 35:5–49.PubMedGoogle Scholar
  11. 11.
    Manji HK, Drevets WC, Charney DS: The cellular neurobiology of depression. Nat Med 2001; 7:541–547.PubMedCrossRefGoogle Scholar
  12. 12.
    Berton O, Nestler EJ: New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7:137–151.PubMedCrossRefGoogle Scholar
  13. 13.
    Vermetten E, Vythilingam M, Southwick SM, et al.: Longterm treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiat 2003; 54:693–702.PubMedCrossRefGoogle Scholar
  14. 14.
    Pacher P, Kecskemeti V: Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr Med Chem 2004; 11:925–943.PubMedCrossRefGoogle Scholar
  15. 15.
    Faden AI, Demediuk P, Panter SS, Vink R: The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989; 244:798–800.PubMedCrossRefGoogle Scholar
  16. 16.
    Panter SS, Faden AI: Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury. Neurosci Lett 1992; 136:165–168.PubMedCrossRefGoogle Scholar
  17. 17.
    Du J, Quiroz JA, Gray NA, et al: Regulation of cellular plasticity and resilience by mood stabilizers. Dialogues Clin Neurosci 2004; 6:143–155.PubMedGoogle Scholar
  18. 18.
    Schechter LE, Ring RH, Beyer CH, et al: Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2005; 2:590–611.PubMedCrossRefGoogle Scholar
  19. 19.
    Bekkers JM, Stevens CF: NMDA and non-NMDA receptors are co-localized at individual excitatory synapses in cultured rat hippocampus. Nature 1989; 341:230–233.PubMedCrossRefGoogle Scholar
  20. 20.
    Miyamoto E: Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J Pharmacol Sci 2006; 100:433–442.PubMedCrossRefGoogle Scholar
  21. 21.
    Lisman JE, McIntyre CC: Synaptic plasticity: a molecular memory switch. Curr Biol 2001; 11:R788–791.PubMedCrossRefGoogle Scholar
  22. 22.
    Calabrese B, Wilson MS, Halpain S: Development and regulation of dendritic spine synapses. Physiology (Bethesda) 2006; 21:38–47.CrossRefGoogle Scholar
  23. 23.
    Hering H, Sheng M: Dendritic spines: structure, dynamics and regulation. Nat Rev Neurosci 2001; 2:880–888.PubMedCrossRefGoogle Scholar
  24. 24.
    Chen PE, Wyllie DJA: Pharmacological insights obtained from structure-function studies of inotropic glutamate receptors. Br J Pharmacol 2006; 147:839–853.PubMedCrossRefGoogle Scholar
  25. 25.
    Bredt DS, Nicoll RA: AMPA receptor trafficking at excitatory synapses. Neuron 2003:40; 361–379.PubMedCrossRefGoogle Scholar
  26. 26.
    Ehlers MD: Reinsertion of degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron 2000; 28:511–525.PubMedCrossRefGoogle Scholar
  27. 27.
    Esteban JA: AMPA receptor trafficking: a road map for synaptic plasticity. Mol Interv 2003; 3:375–385.PubMedCrossRefGoogle Scholar
  28. 28.
    Goldstein LS, Yang Z: Microtubule-based transport systems in neurons: the roles of kinesins and dyneins. Annu Rev Neurosci. 2000; 23:39–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhu C, Zhao J, Bibikova M, et al.: Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell 2005; 16:3187–3199.PubMedCrossRefGoogle Scholar
  30. 30.
    Fischer M, Kaech S, Knutti D, Matus A: Rapid actin-based plasticity in dendritic spines. Neuron 1998; 20:847–854.PubMedCrossRefGoogle Scholar
  31. 31.
    Lowy MT, Wittenberg L, Yamamoto BK: Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem 1995; 65:268–274.PubMedCrossRefGoogle Scholar
  32. 32.
    Lowy MT, Gault L, Yamamoto BK: Adrenalectomy attenuates stress-induced elevations in extracellular glutamate concentrations in the hippocampus. J Neurochem 1993; 61:1957–1960.PubMedCrossRefGoogle Scholar
  33. 33.
    Virgin CE, Ha TP, Packan DR, et al: Glucocorticoids inhibit glucose transport and glutamate uptake in hippocampal astrocytes: implications for glucocorticoid neurotoxicity. J Neurochem 1991; 57:1422–1428.PubMedCrossRefGoogle Scholar
  34. 34.
    Watanabe Y, Gould E, Daniels DC, et al: Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 1992; 222:157–162.PubMedCrossRefGoogle Scholar
  35. 35.
    Magariños AM, McEwen BS: Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 1995; 69:89–98.PubMedCrossRefGoogle Scholar
  36. 36.
    Zarate CA Jr, Du J, Quiroz J, et al.: Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 2003; 1003:273–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Rocher C, Spedding M, Munoz C, Jay TM: Acute stressinduced changes in hippocampal/prefrontal circuits in rats:effects of antidepressants. Cereb Cortex 2004; 14:224–229.PubMedCrossRefGoogle Scholar
  38. 38.
    Sapolsky R: Stress, the Aging Brain and the Mechanisms of Neuron Death. Cambridge, MA: MIT Press, 1992: 1:423.Google Scholar
  39. 39.
    Barria A, Muller D, Derkach V, et al: Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. Science 1997; 276:2042–2045.PubMedCrossRefGoogle Scholar
  40. 40.
    Roche KW, O’Brien RJ, Mammen AL, et al.: Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 1996;16:1179–1188.PubMedCrossRefGoogle Scholar
  41. 41.
    Du J, Suzuki K, Wei Y, et al.: The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007; 32:793–802.PubMedCrossRefGoogle Scholar
  42. 42.
    Svenningsson P, Tzavara ET, Witkin JM, et al.: Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioural effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A 2002; 99:3182–3187.PubMedCrossRefGoogle Scholar
  43. 43.
    Magariños AM, Deslandes A, McEwen BS: Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 1999; 371:113–122.PubMedCrossRefGoogle Scholar
  44. 44.
    McEwen BS and Chattarji S: Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. European Neuropsych 2004; 14Suppl uppl 5:S497–502.CrossRefGoogle Scholar
  45. 45.
    Reznikov LR, Grillo CA, Piroli GG, et al.: Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment. Eur J Neurosci 2007; 25: 3109–3114.PubMedCrossRefGoogle Scholar
  46. 46.
    Kole MH, Swan I, Fuchs E: The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associated synapse in chronically stressed rats. Eur J Neurosci 2002; 16:807–816.PubMedCrossRefGoogle Scholar
  47. 47.
    Reagan LP, Rosell DR, Wood GE, et al.: Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. Proc Natl Acad Sci U S A 2004; 101:2179–2184.PubMedCrossRefGoogle Scholar
  48. 48.
    Czéh B, Michaelis T, Watanabe T, et al.: Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 2001; 98:12796–12801.PubMedCrossRefGoogle Scholar
  49. 49.
    Lucassen PJ, Fuchs E, Czeh B: Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry 2004; 55:789–796.PubMedCrossRefGoogle Scholar
  50. 50.
    Mocaër E, Rettori MC, Kamoun A: Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase. Clin Neuropharmacol 1988; 11Suppl uppl 2:S32–42.PubMedGoogle Scholar
  51. 51.
    Qi H, Mailliet F, Spedding M, et al: Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. Neuropharmacology 2009; 56:37–46.PubMedCrossRefGoogle Scholar
  52. 52.
    Steru L, Chermat R, Thierry B, Simon P: The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985; 85:367–370.CrossRefGoogle Scholar
  53. 53.
    Popoli M, Vocaturo C, Perez J, et al.: Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake. Mol Pharmacol 1995; 48:623–629.PubMedGoogle Scholar
  54. 54.
    Jeon SH, Seong YS, Juhnn YS: Electroconvulsive shock increases the phosphorylation of cyclic AMP response element binding protein at Ser-133 in rat hippocampus but not in cerebellum. Neuropharmacology. 1997; 36:411–414.PubMedCrossRefGoogle Scholar
  55. 55.
    Beck CH: Acute treatment with antidepressant drugs selectively increases the expression of c-fos in the rat brain. J Psychiatry Neurosci 1995; 20:25–32.PubMedGoogle Scholar
  56. 56.
    Morinobu S, Strausbaugh H, Terwilliger R, Duman RS: Regulation of c-Fos and NGF1-A by antidepressant treatments. Synapse 1997; 25:313–320.PubMedCrossRefGoogle Scholar
  57. 57.
    Duncan GE, Knapp DJ, Johnson KB, Breese GR: Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J Pharmacol Exp Ther 1996; 277:1076–1089.PubMedGoogle Scholar
  58. 58.
    Yamamoto BK, Reagan LP: The glutamatergic system in neuronal plasticity and vulnerability in mood disorders. Neuropsychiatr Dis Treat 2006; 2Suppl 2:7–13.Google Scholar

Copyright information

© Springer Healthcare, a part of Springer Science+Business Media 2011

Authors and Affiliations

  • Per Svenningsson
  • Bruce S. McEwen

There are no affiliations available

Personalised recommendations